Vaxcyte, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
PCVX$67.53+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $173,959 | $387,878 |
| Short-term investments | 1,387,000 | 1,359,330 |
| Prepaid expenses and other current assets | 66,402 | 40,777 |
| Total current assets | 1,627,361 | 1,787,985 |
| Property and equipment, net | 257,370 | 198,045 |
| Operating lease right-of-use assets | 116,009 | 72,102 |
| Long-term investments | 881,664 | 1,387,510 |
| Restricted cash | 1,466 | 1,317 |
| Other assets | 118,847 | 64,359 |
| Total noncurrent assets | 1,375,356 | 1,723,333 |
| Total assets | $3,002,717 | $3,511,318 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $70,904 | $48,452 |
| Accrued compensation | 23,000 | 20,555 |
| Accrued contract manufacturing expenses | 74,654 | 36,159 |
| Accrued expenses | 31,068 | 29,123 |
| Operating lease liabilities — current | 6,124 | 5,891 |
| Total current liabilities | 205,750 | 140,180 |
| Operating lease liabilities — long-term | 111,357 | 65,219 |
| Other liabilities | 100 | 100 |
| Total liabilities | 317,207 | 205,499 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' Equity | ||
| Preferred stock, $0.001 par value — 10,000,000 authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value — 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 131,058,858 and 124,893,034 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 134 | 128 |
| Additional paid-in capital | 4,838,736 | 4,697,883 |
| Accumulated other comprehensive income (loss) | 1,587 | (3,873) |
| Accumulated deficit | (2,154,947) | (1,388,319) |
| Total stockholders' equity | 2,685,510 | 3,305,819 |
| Total liabilities and stockholders' equity | $3,002,717 | $3,511,318 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.